LIGAND PHARMACEUTICALS INC Form SC 13G/A January 20, 2005

OMB APPROVAL

OMB Number: 3235-0145

Expires: December 31, 2005

Estimated average burden hours per response...11

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

#### LIGAND PHARMACEUTICALS INCORPORATED

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

53220K207

(Cusip Number)

January 14, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1 (b)

X Rule 13d-1 (c)

o Rule 13d-1 (d)

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

Page 1 of 6

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. :	53220	K207		
1. N	Name of Reporting Person: BB Biotech AG		I.R.S. Identification Nos. of above persons (entities only): N/A	
(	Check  a) X  b) O		per of a Group:	
3. S	SEC U	se Only:		
	Citizen Switzer	ship or Place of Organization: rland		
Number of		Sole Voting Power:		
Shares Beneficially Owned by Each Reporting Person With	6.	Shared Voting Power: 3,655,400		
	h 7.	Sole Dispositive Power:		
	8.	Shared Dispositive Power: 3,655,400		
9. A	Aggreg 5,655,4	gate Amount Beneficially Owne 100	ed by Each Reporting Person:	
10. C		if the Aggregate Amount in Ro	w (9) Excludes Certain Shares:	
11. F	Percent	t of Class Represented by Amou	unt in Row (9):	

4.9%

12. Type of Reporting Person: HC, CO

Page 2 of 6

CUSIP No	. 532	20K	207				
1.	Name of Reporting Person: Biotech Invest N.V.		Reporting Person: Invest N.V.	I.R.S. Identification Nos. of above persons (entities only): N/A			
	<ul> <li>Check the Appropriate Box if a Member of a Group:</li> <li>(a) x</li> <li>(b) 0</li> </ul>						
3.	SEC	Use	e Only:				
			nip or Place of Organization: nds Antilles				
Number of		5.	Sole Voting Power:				
Shares Beneficially Owned by Each Reporting Person With	lly by ig	6.	Shared Voting Power: 3,655,400				
	ith	7.	Sole Dispositive Power:				
		8.	Shared Dispositive Power: 3,655,400				
	Agg 3,65		te Amount Beneficially Owned by Ea 0	ch Reporting Person:			
10.	Chec	ck if	the Aggregate Amount in Row (9) Ex	ccludes Certain Shares:			
11.	Perc	ent o	of Class Represented by Amount in Ro	ow (9):			

4.9%

12. Type of Reporting Person: CO

Page 3 of 6

#### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned:	3,655,400	
(b)	Percent of class:	4.9%	
(c)	Number of shares as to which the person has:		
	(i) Sole power to vote or to direct the vote		0
	(ii) Shared power to vote or to direct the vote		3,655,400
	(iii) Sole power to dispose or to direct the disposition of		0
	(iv) Shared power to dispose or to direct the disposition of		3,655,400

#### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

#### **Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 4 of 6

#### **SIGNATURES**

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**BB Biotech AG** 

Date: January 19, 2005 By: /s/ Pascal Schmucki

Signatory Authority

Name: Pascal Schmucki

Title: Signatory Authority

Date: January 19, 2005 By: /s/ Adrian Bruengger

Signatory Authority

Name: Adrian Bruengger

Title: Signatory Authority

Biotech Invest N.V.

Date: January 19, 2005 By: /s/ Pascal Schmucki

Signatory Authority

Name: Pascal Schmucki

Title: Signatory Authority

Date: January 19, 2005 By: /s/ Adrian Bruengger

Signatory Authority

Name: Adrian Bruengger

Title: Signatory Authority

Page 5 of 6

### **EXHIBIT INDEX**

Exhibit 1: Agreement by and between BB Biotech and BioInvest with respect to the filing of this disclosure statement.\*

Page 6 of 6

<sup>\*</sup> Previously filed.